BACKGROUND: Emerging evidence suggests that tumour morphological heterogeneity may influence mutational profiles relevant to therapy response. In this pilot study, we aimed to assess whether mutations identified within specific morphological patterns or at the invasion front correlate with shorter time to progression after anti-EGFR therapy, as compared to whole-tissue analysis. METHODS: We investigated genetic mutations in 142 samples from primary tumours of 39 KRAS wild-type metastatic colorectal cancer (CRC) patients receiving anti-EGFR therapy. Deep next-generation sequencing was performed on whole-tumour sections and six morphology-defined tumour regions. RESULTS: Mutations in genes linked to anti-EGFR therapy response (KRAS, BRAF, NRAS, PTEN and PI3KCA) were found uniquely in the non-responder group, with substantial variability across morphological sub-regions. BRAF mutations were aligned with serrated and mucinous morphologies, while KRAS mutations (p.Lys147Glu and p.Ala146Thr) were associated with mucinous and desmoplastic morphologies. In all cases, the cumulative mutational profile from sub-regions provided more details than that of the whole-tumour profile. CONCLUSION: Our findings highlight that comprehensive analysis, considering morphological heterogeneity, is crucial for personalised CRC treatment strategies.

Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Biology Faculty of Medicine Masaryk University Brno Czech Republic

Masaryk Memorial Cancer Institute Brno Czech Republic

RECETOX Faculty of Science Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Sung H., Ferlay J., Siegel R. L., et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209–249. PubMed

Siegel R. L., Miller K. D., Fuchs H. E., and Jemal A., “Cancer Statistics, 2022,” CA: A Cancer Journal for Clinicians 72, no. 1 (2022): 7–33. PubMed

Tabernero J., Van Cutsem E., Díaz‐Rubio E., et al., “Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First‐Line Treatment of Metastatic Colorectal Cancer,” Journal of Clinical Oncology 25, no. 33 (2007): 5225–5232. PubMed

Borner M., Koeberle D., Von Moos R., et al., “Adding Cetuximab to Capecitabine Plus Oxaliplatin (XELOX) in First‐Line Treatment of Metastatic Colorectal Cancer: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research SAKK,” Annals of Oncology 19, no. 7 (2008): 1288–1292. PubMed

Bardelli A. and Siena S., “Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer,” Journal of Clinical Oncology 28, no. 7 (2010): 1254–1261. PubMed

Baisse B., Bouzourene H., Saraga E. P., Bosman F. T., and Benhattar J., “Intratumor Genetic Heterogeneity in Advanced Human Colorectal Adenocarcinoma,” International Journal of Cancer 93, no. 3 (2001): 346–352, 10.1002/ijc.1343. PubMed DOI

Farber L., Efrati E., Elkin H., et al., “Molecular Morphometric Analysis Shows Relative Intra‐Tumoural Homogeneity for KRAS Mutations in Colorectal Cancer,” Virchows Archiv 459, no. 5 (2011): 487–493. PubMed

Jeantet M., Tougeron D., Tachon G., et al., “High Intra‐ and Inter‐Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer,” International Journal of Molecular Sciences 17, no. 12 (2016): 2015. PubMed PMC

Jones H. G., Jenkins G., Williams N., et al., “Genetic and Epigenetic Intra‐Tumour Heterogeneity in Colorectal Cancer,” World Journal of Surgery 41, no. 5 (2017): 1375–1383. PubMed PMC

Büttner J., Jöhrens K., Klauschen F., et al., “Intratumoral Morphological Heterogeneity Can Be an Indicator of Genetic Heterogeneity in Colorectal Cancer,” Experimental and Molecular Pathology 104, no. 1 (2018): 76–81. PubMed

Reggiani‐Bonetti L., Barresi V., Bettelli S., Caprera C., Manfredini S., and Maiorana A., “Analysis of KRAS, NRAS, PIK3CA, and BRAF Mutational Profile in Poorly Differentiated Clusters of KRAS‐Mutated Colon Cancer,” Human Pathology 62 (2017): 91–98. PubMed

Normanno N., Rachiglio A. M., Lambiase M., et al., “Heterogeneity of KRAS, NRAS, BRAF and PIK3CA Mutations in Metastatic Colorectal Cancer and Potential Effects on Therapy in the CAPRI GOIM Trial,” Annals of Oncology 26, no. 8 (2015): 1710–1714. PubMed

Fassan M., “Molecular Diagnostics in Pathology: Time for a Next‐Generation Pathologist?,” Archives of Pathology & Laboratory Medicine 142, no. 3 (2018): 313–320. PubMed

Lamont A. and Pottie R., “Versatility of Soft‐Tissue Free Tissue Transfers,” South African Journal of Surgery 26, no. 3 (1988): 98–101. PubMed

Pang S.‐W., Awi N. J., Armon S., et al., “Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC),” Diagnostics (Basel) 10, no. 1 (2019): 9, 10.3390/diagnostics10010009. PubMed DOI PMC

Budinska E., Popovici V., Tejpar S., et al., “Gene Expression Patterns Unveil a New Level of Molecular Heterogeneity in Colorectal Cancer,” Journal of Pathology 231, no. 1 (2013): 63–76. PubMed PMC

Budinská E., Hrivňáková M., Ivkovic T. C., et al., “Molecular Portraits of Colorectal Cancer Morphological Regions,” eLife 12 (2023): RP86655. PubMed PMC

Dragomir M. P., Popovici V., Schallenberg S., et al., “A quantitative tumor‐wide analysis of morphological heterogeneity of colorectal adenocarcinoma,” 2024. bioRxiv 2024.04.10.588907, 10.1101/2024.04.10.588907. DOI

R Core Team , R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing; ) (2022).

Peng J., Liu Y., Li W., et al., “Application of Tumor Burden Score for Predicting Conversion Outcome in Patients With Initially Unresectable Colorectal Liver Metastases After First‐Line Systemic Therapy,” Therapeutic Advances in Gastroenterology 14 (2021): 1–16. PubMed PMC

Laurent‐Puig P., Cayre A., Manceau G., et al., “Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild‐Type KRAS Metastatic Colon Cancer,” Journal of Clinical Oncology 27, no. 35 (2009): 5924–5930. PubMed

Douillard J.‐Y., Oliner K. S., Siena S., et al., “Panitumumab‐FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer,” New England Journal of Medicine 369, no. 11 (2013): 1023–1034. PubMed

Cremolini C., Rossini D., Dell'Aquila E., et al., “Rechallenge for Patients With RAS and BRAF Wild‐Type Metastatic Colorectal Cancer With Acquired Resistance to First‐Line Cetuximab and Irinotecan: A Phase 2 Single‐Arm Clinical Trial,” JAMA Oncology 5, no. 3 (2019): 343–350, 10.1001/jamaoncol.2018.5080. PubMed DOI PMC

Segelov E., Thavaneswaran S., Waring P. M., et al., “Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro‐Intestinal Trials Group ICECREAM Study,” Journal of Clinical Oncology 34, no. 19 (2016): 2258–2264, 10.1200/JCO.2015.65.6843. PubMed DOI

Schirripa M., Loupakis F., Lonardi S., et al., “Phase II Study of Single‐Agent Cetuximab in KRAS G13D Mutant Metastatic Colorectal Cancer,” Annals of Oncology 26, no. 12 (2015): 2503. PubMed

Van Cutsem E., Köhne C.‐H., Hitre E., et al., “Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer,” New England Journal of Medicine 360, no. 14 (2009): 1408–1417. PubMed

Karapetis C. S., Khambata‐Ford S., Jonker D. J., et al., “K‐Ras Mutations and Benefit From Cetuximab in Advanced Colorectal Cancer,” New England Journal of Medicine 359, no. 17 (2008): 1757–1765. PubMed

Van Emburgh B. O., Sartore‐Bianchi A., Di Nicolantonio F., Siena S., and Bardelli A., “Acquired Resistance to EGFR‐Targeted Therapies in Colorectal Cancer,” Molecular Oncology 8, no. 6 (2014): 1084–1094. PubMed PMC

Vaughn C. P., Zobell S. D., Furtado L. V., Baker C. L., and Samowitz W. S., “Frequency of KRAS, BRAF, and NRAS Mutations in Colorectal Cancer,” Genes, Chromosomes & Cancer 50, no. 5 (2011): 307–312. PubMed

Edkins S., O'Meara S., Parker A., et al., “Recurrent KRAS Codon 146 Mutations in Human Colorectal Cancer,” Cancer Biology & Therapy 5, no. 8 (2006): 928–932. PubMed PMC

Janakiraman M., Vakiani E., Zeng Z., et al., “Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer,” Cancer Research 70, no. 14 (2010): 5901–5911. PubMed PMC

Smith G., Bounds R., Wolf H., Steele R. J. C., Carey F. A., and Wolf C. R., “Activating K‐Ras Mutations Outwith “Hotspot” Codons in Sporadic Colorectal Tumours—Implications for Personalised Cancer Medicine,” British Journal of Cancer 102, no. 4 (2010): 693–703. PubMed PMC

Jones J. C., Renfro L. A., Al‐Shamsi H. O., et al., “Non‐V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer,” Journal of Clinical Oncology 35, no. 23 (2017): 2624–2630. PubMed PMC

Richman S. D., Chambers P., Seymour M. T., et al., “Intra‐Tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients With Advanced Colorectal Cancer (aCRC) and Cost‐Effectiveness of Multiple Sample Testing,” Analytical Cellular Pathology (Amsterdam) 34, no. 1–2 (2011): 61–66. PubMed PMC

Santos C., Azuara D., Garcia‐Carbonero R., et al., “Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti‐EGFR Treatment in Metastatic Colorectal Cancer,” Molecular Cancer Therapeutics 16, no. 9 (2017): 1999–2007. PubMed

Sato T., Osumi H., Shinozaki E., et al., “Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third‐Line Chemotherapy for Metastatic Colorectal Cancer,” Anticancer Research 41, no. 8 (2021): 3905–3915. PubMed

Tural D., Batur S., Erdamar S., et al., “Analysis of PTEN, BRAF and PI3K Status for Determination of Benefit From Cetuximab Therapy in Metastatic Colorectal Cancer Patients Refractory to Chemotherapy With Wild‐Type KRAS,” Tumour Biology 35, no. 2 (2014): 1041–1049. PubMed

Baldus S. E., Schaefer K.‐L., Engers R., Hartleb D., Stoecklein N. H., and Gabbert H. E., “Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases,” Clinical Cancer Research 16, no. 3 (2010): 790–799. PubMed

Losi L., Baisse B., Bouzourene H., and Benhattar J., “Evolution of Intratumoral Genetic Heterogeneity During Colorectal Cancer Progression,” Carcinogenesis 26, no. 5 (2005): 916–922. PubMed

Kosmidou V., Oikonomou E., Vlassi M., et al., “Tumor Heterogeneity Revealed by KRAS, BRAF, and PIK3CA Pyrosequencing: KRAS and PIK3CA Intratumor Mutation Profile Differences and Their Therapeutic Implications,” Human Mutation 35, no. 3 (2014): 329–340. PubMed

Brannon A. R., Vakiani E., Sylvester B. E., et al., “Comparative Sequencing Analysis Reveals High Genomic Concordance Between Matched Primary and Metastatic Colorectal Cancer Lesions,” Genome Biology 15, no. 8 (2014): 454. PubMed PMC

Santini D., Loupakis F., Vincenzi B., et al., “High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice,” Oncologist 13, no. 12 (2008): 1270–1275. PubMed

De Roock W., Claes B., Bernasconi D., et al., “Effects of KRAS, BRAF, NRAS, and PIK3CA Mutations on the Efficacy of Cetuximab Plus Chemotherapy in Chemotherapy‐Refractory Metastatic Colorectal Cancer: A Retrospective Consortium Analysis,” Lancet Oncology 11, no. 8 (2010): 753–762. PubMed

Sartore‐Bianchi A., Di Nicolantonio F., Nichelatti M., et al., “Multi‐Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR‐Targeted Monoclonal Antibodies in Colorectal Cancer,” PLoS One 4, no. 10 (2009): e7287. PubMed PMC

Cancer Genome Atlas Network , “Comprehensive Molecular Characterization of Human Colon and Rectal Cancer,” Nature 487, no. 7407 (2012): 330–337, 10.1038/nature11252. PubMed DOI PMC

Perrone F., Lampis A., Orsenigo M., et al., “PI3KCA/PTEN Deregulation Contributes to Impaired Responses to Cetuximab in Metastatic Colorectal Cancer Patients,” Annals of Oncology 20, no. 1 (2009): 84–90. PubMed

Karapetis C. S., Jonker D., Daneshmand M., et al., “PIK3CA, BRAF, and PTEN Status and Benefit From Cetuximab in the Treatment of Advanced Colorectal Cancer—Results From NCIC CTG/AGITG CO.17,” Clinical Cancer Research 20, no. 3 (2014): 744–753, 10.1158/1078-0432.CCR-13-0606. PubMed DOI

Martini G., Ciardiello D., Vitiello P. P., et al., “Resistance to Anti‐Epidermal Growth Factor Receptor in Metastatic Colorectal Cancer: What Does Still Need to Be Addressed?,” Cancer Treatment Reviews 86 (2020): 102023. PubMed

Waldstein S., Spengler M., Pinchuk I. V., and Yee N. S., “Impact of Colorectal Cancer Sidedness and Location on Therapy and Clinical Outcomes: Role of Blood‐Based Biopsy for Personalized Treatment,” Journal of Personalized Medicine 13, no. 7 (2023): 1114. PubMed PMC

Salem M. E., Battaglin F., Goldberg R. M., et al., “Molecular Analyses of Left‐ and Right‐Sided Tumors in Adolescents and Young Adults With Colorectal Cancer,” Oncologist 25, no. 5 (2020): 404–413. PubMed PMC

Abravanel D. L., Belka G. K., Pan T., et al., “Notch Promotes Recurrence of Dormant Tumor Cells Following HER2/Neu‐Targeted Therapy,” Journal of Clinical Investigation 125, no. 6 (2015): 2484–2496. PubMed PMC

Tyagi A., Sharma A. K., and Damodaran C., “A Review on Notch Signaling and Colorectal Cancer,” Cells 9, no. 6 (2020): 1549. PubMed PMC

Dang D. K. and Park B. H., “Circulating Tumor DNA: Current Challenges for Clinical Utility,” Journal of Clinical Investigation 15, no. 12 (2022): e154941. PubMed PMC

Kim H. and Park K. U., “Clinical Circulating Tumor DNA Testing for Precision Oncology,” Cancer Research and Treatment 55, no. 2 (2023): 351–366. PubMed PMC

Ottaiano A., Circelli L., and Caraglia M., “The Tumor Dynamism Is the Dark Matter of the NGS Galaxy: How to Understand It?,” Cancers (Basel) 13, no. 21 (2021): 5476. PubMed PMC

Ottaiano A., Ianniello M., Santorsola M., et al., “From Chaos to Opportunity: Decoding Cancer Heterogeneity for Enhanced Treatment Strategies,” Biology (Basel) 12, no. 9 (2023): 1183, 10.3390/biology12091183. PubMed DOI PMC